Hematology

Pharmacokinetic differences in pediatric patients should be considered when administering direct oral anticoagulants, as should potential administration difficulties when pellets or oral solutions are not available.

Selection of any BTK inhibitors for mantle cell lymphoma should consider factors such as cardiovascular or bleeding risks, predisposition for gastrointestinal adverse effects, and potential medication nonadherence.

CLL is the most common leukemia in adult patients in the western world, with 21,040 estimated new cases in 2020.

Promising investigational oncology drugs include oral taxanes, small molecule drugs, and immunotherapies.

Common factors that contributed to reported increased dissatisfaction at work include role conflict, quantity of work, workflow disruptions, organizational culture, and leadership support.

Even while therapeutically anticoagulated, patients with cancer have risk factors for recurring venous thromboembolism and bleeding, according to a session at the Hematology/Oncology Pharmacy Association 2021 Virtual Annual Conference.

During the initial CAR T-cell therapy period, the total cost of care ranged from $350,000 to more than $2 million.

In a presentation at the Community Oncology Alliance 2021 Virtual Conference, Jeff Sharman, MD, summarized the most important developments in care for CLL.

The researchers found that patients who reduced their calorie intake by 10% or more and adopted a moderate exercise program immediately after their diagnosis had, on average, 70% less chance of having lingering leukemia cells after a month of chemotherapy than those not on the diet-and-exercise regimen.

According to previous studies, youth who are obese when they begin chemotherapy are more than twice as likely to have remaining cancer cells after 1 month of treatment compared to their lean counterparts.

As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape.

In this high-risk population, strategies for minimizing viral exposure during a pandemic are being considered with oncology treatment options.

Isatuximab in combination with carfilzomib and dexamethasone reduced the risk of disease progression or death by 45% versus standard of care alone.

Although pediatric patients represent a small portion of total acute myeloid leukemia cases, clinicians said there is a critical need for more effective therapies in this population.

Anti-inflammatory therapies could be effective at preventing heart disease in patients with clonal hematopoiesis, a common age-related blood condition, according to a new study published in Nature.

In a clinical trial of idecabtagene vicleucel in multiple myeloma, the overall response rate for the efficacy evaluable population was 72%, and 28% of participants achieved a stringent complete response.

Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.

The FDA has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.

Investigators recommended avoiding risk factors such as smoking and switching to a transdermal administration route for testosterone.

The FDA has approved melphalan flufenamide (Pepaxto; melflufen) for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.

Study findings illustrate the need for better communication between health care providers and patients experiencing concerns during the pandemic.

Study findings suggest that enhanced cleaning and disinfecting policies are effective at reducing the spread of COVID-19.

A more sensitive test capable of detecting heart function issues early in cancer treatment may be beneficial in preventing heart failure.

The research will have implications for clinicians when prescribing blood-thinning medications after Fontan surgery, a complex congenital heart disease operation redirecting blood flow from the lower body to the lungs.

Presentation provides an overview of recent FDA approvals for therapies utilized in patients with various cancer types.

Health care providers should monitor blood pressure starting in early adolescence, especially for individuals at high cardiovascular risk, such as Black populations.

Data show that 1 in 5 men and women worldwide develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease, according to the study.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic the next steps for his CAEL-101 findings, a treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic his recent CAEL-101 findings, and how it can help shape treatment for patients living with amyloid light chain amyloidosis.